Fortvita Receives Its First Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer
Fortvita Receives Its First Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer |
| [16-November-2026] |
The opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is Fortvita's first European regulatory milestone; if approved, Zybrivo would expand first-line treatment options for eligible patients with lung cancer in Europe PALO ALTO, Calif., Nov. 16, 2026 /PRNewswire/ -- Fortvita Biologics (Fortvita), a member of the Innovent Group (Innovent Biologics, Inc., HKEX Stock Code: 01801), today announced that it has received its first positive opinion from the CHMP of the European Medicines Agency (EMA). The CHMP recommends marketing authorization of Zybrivo® (sintilimab) in combination with chemotherapy for the first-line treatment of eligible adults with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo would provide eligible patients across Europe with access to another first-line treatment option. The positive opinion is supported by results from the Phase 3 ORIENT-11 study (NCT03607539).
"This positive CHMP opinion marks a significant milestone in Fortvita's globalization journey and reinforces our commitment to bringing innovative therapies to patients worldwide," said Jamie Freedman, MD, PhD, Chief Medical Officer of Fortvita. "Europe is a key pillar of Fortvita's globalization strategy to bring innovative medicines to patients beyond China. As we await the European Commission's decision, we are strengthening our capabilities to support patient access across key European markets. If approved, Zybrivo would be our first medicine to advance this strategy, offering an additional treatment option for eligible patients with advanced non-squamous non-small cell lung cancer and paving the way for future therapies from our growing pipeline." Following the CHMP's positive opinion, the European Commission is expected to issue a final decision on marketing authorization in the coming months. If approved, the authorization will be valid across all 27 European Union (EU) member states, as well as Iceland, Norway, and Liechtenstein. Sintilimab is an immunotherapy consisting of a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1). The CHMP recommendation is based on results of ORIENT-11, a randomized, multicenter, double-blind, placebo-controlled Phase 3 study that enrolled 397 adult patients with locally advanced, metastatic or recurrent non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations, regardless of programmed death-ligand 1 (PD-L1) expression. Patients were randomized 2:1 to receive sintilimab or placebo, each in combination with pemetrexed and platinum-based chemotherapy. The primary endpoint was progression-free survival (PFS), assessed by a blinded independent radiological review committee. In ORIENT-11, sintilimab plus chemotherapy demonstrated a 52% reduction in the hazard of disease progression or death (median PFS: 8.9 vs. 5.0 months) and a 35% reduction in the hazard of death (median overall survival (OS): 24.2 vs. 16.8 months), compared with placebo plus chemotherapy. These results demonstrate the clinical benefit of sintilimab in combination with chemotherapy and its potential to offer an additional first-line treatment option for eligible patients with advanced non-squamous NSCLC in Europe. The safety profile of sintilimab in combination with chemotherapy was consistent with the known safety profiles of PD-1 inhibitors and the chemotherapy agents used, with no new safety signals identified. Additional details may be found at clinicaltrials.gov, using identifier NCT03607539. Zybrivo in combination with pemetrexed and platinum-based chemotherapy is indicated for the first line treatment of adult non-squamous non-small cell lung cancer (NSCLC) patients with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations, and who have: About Non-Small Cell Lung Cancer About Sintilimab Sintilimab has been approved in China for ten indications, covering squamous non-small cell lung cancer, non-squamous non-small cell lung cancer (including EGFR/ALK wild type non-squamous NSCLC and EGFR tyrosine kinase inhibitor (TKI) treatment failure non-squamous NSCLC), hepatocellular carcinoma, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell cancer, endometrial cancer, colon cancer, renal cell carcinoma and classical Hodgkin's lymphoma. In China, sintilimab has been used to treat approximately 3 million patients.5 Important Safety Information This information is intended for a global audience. Product indications vary by region. About Fortvita Headquartered in the San Francisco Bay Area, Fortvita combines Innovent's strengths in discovery, development and manufacturing with its own development and commercial capabilities across Asia, Europe, Australia and the United States. Its portfolio is focused on oncology and is expanding into cardiovascular and metabolic diseases, autoimmune diseases and ophthalmology. Learn more at www.fortvitabio.com or follow Fortvita on LinkedIn. About Innovent Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the high-quality outbound internationalization of China's innovative drug industry. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Statement References
Forward-Looking Statements These forward-looking statements are based on current beliefs, assumptions, expectations, estimates, projections, and understandings of Fortvita's management with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Fortvita's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements due to factors including, but not limited to, the timing, progress, and results of clinical trials, regulatory approvals, manufacturing capabilities, competition, and changes in political, economic, legal, and social conditions. Fortvita, its Directors and employees assume (a) no obligation to correct or update any forward-looking statements contained in this release, and (b) no liability in the event that any of the forward-looking statements do not materialize or turn out to be incorrect.
| ||
Company Codes: HongKong:01801 |












